Camurus
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Sweden · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Ideon Science Park, Lund, Skane, 223 70,...Phone Number
+46 462865730Website
www.camurus.comRevenue
$213.2 MillionStock Symbol
CAMXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Camurus
Camurus is a Swedish biopharmaceutical company focused on improving the lives of patients with severe and chronic diseases. The company develops innovative treatments for conditions such as opioid dependence, acromegaly, neuroendocrine tumors, and other rare diseases within the central nervous system, endocrinology, oncology, and supportive care. Their diversified pipeline aims to address significant unmet medical needs, enhancing treatment outcomes and quality of life for patients. Camurus is committed to sustainability and responsible business practices while delivering better health solutions globally.Explore more
Camurus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Camurus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Camurus
Check out if Camurus is spiking on competitors!
Camurus, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Camurus launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Camurus has recently received funding, and reach out quickly before it becomes old news!
Click to see if Camurus had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Camurus has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Camurus recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Camurus as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Camurus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Camurus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Camurus.
Camurus Tech Stack
A closer look at the technologies used by Camurus
Most Recent Scoops
Partnership
Camurus has extended its collaboration with Eli Lilly to include amylin, broadening the partnership to now cover three substance classes: dual GLP-1, triple G (including glucagon), and amylin. This expansion represents a broad and deepening collaboration across multiple drug modality areas.
Partnership
Pain Point
experienced a negative impact on Q1 performance following a distribution model change in the UK implemented in Q4 2025, driven by stock phasing and distributor transition effects. The situation is now normalizing, with the company expecting healthy growth to resume in Q3 and Q4 of the year.
Pain Point
Pain Point
experienced a negative impact on Q1 performance following a distribution model change in the UK implemented in Q4 2025, driven by stock phasing and distributor transition effects. The situation is now normalizing, with the company expecting healthy growth to resume in Q3 and Q4 of the year.
Pain Point
Pain Point
faced a funding constraint in England in 2025, where a one-year community treatment budget limited clinician interest in initiating long-term treatment courses with new therapies. This constraint has since been resolved with the establishment of a 3-year funding framework, and the company expects the UK market to return to planned growth in 2026.
Pain Point
Pain Point
Pain Point
Camurus News & Media
Camurus announces expansion of Lilly collaboration
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's...Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDTCompany ParticipantsRein Piir - Vice President of Investor RelationsFredrik Tiberg -...Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call February 12, 2026 8:00 AM ESTCompany ParticipantsFredrik Tiberg - President, CEO, CSO & DirectorAnders...Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
PDUFA target action date set to 10 June 2026 LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029),...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Camurus
Sign Up For FreeTo access detailed company insights
Camurus is a Swedish biopharmaceutical company focused on improving the lives of patients with severe and chronic diseases. The company develops innovative treatments for conditions such as opioid dependence, acromegaly, neuroendocrine tumors, and other rare diseases within the central nervous system, endocrinology, oncology, and supportive care. T... Read More
